Yale School of Medicine Launches Yale Biomedical Imaging Institute
NEW HAVEN, Conn.,
"The Yale Biomedical Imaging Institute brings together world-class talent and resources to accelerate discovery and impact across medicine," says
The Yale Biomedical Imaging Institute emerged from a year-long strategic planning initiative led by YSM
The institute aims to:
- Create novel biomedical imaging technologies across diverse modalities
- Translate discoveries to guide diagnostics and therapies
- Apply artificial intelligence and data science to enhance research and clinical care
The institute will integrate the work of longstanding Yale centers and cores—including the Positron Emission Tomography (PET) Center and Magnetic Resonance Research Center—along with data science and imaging informatics expertise. Initial initiatives will include training opportunities for postdocs and students, along with exploratory funding opportunities.
"There is an unparalleled opportunity at Yale to establish a world-class imaging institute based on the strength of its existing programs," says
"This institute solidifies Yale's decades-long leadership in imaging and ensures we remain at the forefront of translational and clinical research," says Rothman.
About the Yale School of Medicine
Yale School of Medicine educates leaders in medicine and science, fostering curiosity and critical inquiry. It is a global leader in biomedical research, clinical care, and medical education. With over 1,700 physicians, Yale provides compassionate care to patients worldwide. The Yale System of Medical Education emphasizes critical thinking and independent research, producing leaders in academic medicine.
View original content to download multimedia:https://www.prnewswire.com/news-releases/yale-school-of-medicine-launches-yale-biomedical-imaging-institute-302487177.html
SOURCE Yale School of Medicine
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flagship Pioneering Awarded First-Of-Its-Kind Contract by Department of War to Advance Next-Generation Medical Countermeasure Technologies Against Evolving Biological Threats
- Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
- Edsby Forms & Workflows Brings Purpose-Built Digital Approvals to K‑12
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share